Last reviewed · How we verify
NCT06710314
A Metabolomics-based Study to Explore the Mechanism of Remission of Metabolic Syndrome Radical Resection of Colorectal Cancer
trial testing Colorectal cancer patients with hypertension in Metabolomics in 150 participants. Enrolling by invitation.
1 June 2026
Quick facts
| Lead sponsor | Dong Peng |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 July 2024 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Colorectal cancer patients with hypertension
- Colorectal cancer patients with diabetes
- Colorectal cancer patients with fatty liver
Conditions studied
- Metabolomics — all drugs for Metabolomics →
Sponsor
Dong Peng
Who can join
18 and older, any sex, with Metabolomics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. Analysis of preoperative and postoperative metabolite changes: Through metabolomics technology, the changes of preoperative and postoperative metabolites in patients with colorectal cancer complicated with metabolic syndrome such as hypertension and diabetes were systematically analyzed, and the key metabolites related to postoperative remission were found. 2. Explore the influencing factors of postoperative remission of metabolic syndrome: Combined with clinical data, the association between various metabolites and the degree of postoperative remission was evaluated, and the main factors affecting postoperative remission were determined. To reveal the mechanism of the remission of metabolic syndrome after surgery: To clarify the metabolic pathways and mechanisms involved in the remission of metabolic syndrome after surgery through multi-level metabolomics analysis, and to provide a new theoretical basis for the development of tumor metabolic surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Crosstalk Between Metabolic Reprogramming and Epigenetic Modifications in Colorectal Cancer: Mechanisms and Clinical Applications.
Sun YH, Zhang JX, Jin HS, Huang J. · · 2025 · cited 3× · PMID 41020873 · DOI 10.3390/cimb47090751
Verify or expand the search:
- PubMed search for NCT06710314
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolomics
Currently open trials in the same condition.
- NCT07392905 — Food Intake-Related Brain and Metabolic Responses in Obesity · NA · recruiting
- NCT06951386 — The Impact of Daily Intake of Short-chain Fatty Acids on Cardiometabolic Risk Factors in Individuals at Risk for Metabol · NA · recruiting
- NCT06614660 — Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer · active not recruiting
- NCT06073470 — Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With A · recruiting
- NCT06843707 — Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. · recruiting
Other Dong Peng trials
Trials by the same sponsor.
- NCT07126743 — Organic Pollutant Build-Up in Body Fat and Stomach Tissue Linked to Obesity Levels · active not recruiting
- NCT07063550 — Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer · active not recruiting
- NCT06856382 — The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer · active not recruiting
- NCT06854146 — The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome · active not recruiting
- NCT06852495 — the Effect of Environmental Factors on Colorectal Cancer Based on Macrogenomes · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06710314 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dong Peng
- Last refreshed: 29 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06710314.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing